MedTrace Logo

Study Of Bioavailability Of Two Sildenafil 100mg Oral Tablet Formulations

NCT00902512 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-02-01

No results posted yet for this study

Summary

the pharmacokinetics of sildenafil following single doses of sildenafil CT administered with and without water is similar relative to the conventional oral tablet of sildenafil administered with water.

Conditions

  • Healthy Males

Interventions

DRUG

Treatment A

Viagra® 100 mg tablet, administered with water single dose

DRUG

Blood samples for the analysis of sildenafil in plasma

Blood samples for the analysis of sildenafil in plasma

DRUG

Treatment B

Sildenafil 100 mg CT administered with water single dose

OTHER

Blood samples for the analysis of sildenafil in plasma

Blood samples for the analysis of sildenafil in plasma

DRUG

Treatment C

Sildenafil 100 mg CT administered without water single dose

OTHER

Blood samples for the analysis of sildenafil in plasma

Blood samples for the analysis of sildenafil in plasma

Sponsors & Collaborators

  • Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V.

    collaborator OTHER

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • Mexico

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00902512 on ClinicalTrials.gov